What Cardiac Medication is Not Recommended For a Patient With Type 2 Diabetes?

What Cardiac Medication is Not Recommended For a Patient With Type 2 Diabetes? 

The patient with type 2 diabetes should not take TZDs, or other similar cardiac medications, as they may raise their risk of cardiovascular events. People who took TZDs had a 43 percent higher risk of cardiovascular events. However, TZDs may be beneficial for patients who have other conditions, such as coronary artery disease. Besides TZDs, people who are taking insulin and another type 2 diabetes medications should not take Aspirin. 

(For the best diabetes treatment, visit us today!)


Almost half of the participants in the study were prescribed aspirin for their diabetes. Of the 204 non-aspirin users, 22 were previously on aspirin, while 47 were on other antiplatelet/anticoagulant medications. Patients who received aspirin were older, had more chronic conditions, and were more likely to have higher systolic blood pressure. Additionally, aspirin use was more common in patients who had previously received antiplatelet medications. 

Even though aspirin is not recommended for patients with type 2 diabetes, it can prevent cardiovascular events in people with the disease. However, low-dose aspirin should be individualized based on a patient’s baseline risk for bleeding and CVD. Patients with vascular disease should consult their health care provider if they are taking aspirin. Aspirin is also linked to adverse reactions. 


Although the drug is considered an approved treatment for people with type 2 diabetes, there are concerns that it may cause kidney or heart problems. Researchers found that it increased the risk of kidney failure in patients. These patients were also at greater risk of cardiovascular events. For these reasons, the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers is recommended in patients with diabetes. Saxagliptin has been shown to improve kidney function. 

Although the study has not yet published its results, physicians should understand the risks and benefits of the drug. For example, the drug should not be prescribed to patients with type 2 diabetes without the doctor’s consent. Patients should talk to their doctor about the drug’s risks and benefits before taking it. Saxagliptin can lead to cardiovascular complications, including heart failure. 


Alogliptin is an oral medication that can significantly lower HbA1c levels in patients with type 2 diabetes. The drug is effective in lowering the levels of blood sugar without causing any negative side effects, including kidney or liver damage. Many clinical trials have shown that it is safe and effective for patients with type 2 diabetes, which is why it is approved for this use in patients with elevated cardiovascular risk. This drug has a median safety period of 18 months. 

However, despite this favorable safety profile, there are still concerns about cardiovascular side effects associated with type 2 diabetes. The FDA has also mandated that a complete cardiovascular safety assessment be conducted on new antidiabetic drugs. In a recent study, alogliptin was compared to placebo in patients with type 2 diabetes and recent acute coronary syndrome. The new warnings for patients with type 2 diabetes should help prevent any adverse effects from occurring.